Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease

dc.contributor.authorClark, Ian A
dc.contributor.authorVissel, Bryce
dc.date.accessioned2015-12-13T22:30:34Z
dc.date.issued2013
dc.date.updated2016-02-24T09:24:40Z
dc.description.abstractThe disappointments of a series of large anti-amyloid trials have brought home the point that until the driving force behind Alzheimer's disease, and the way it causes harm, are firmly established and accepted, researchers will remain ill-equipped to find
dc.identifier.issn0006-2952
dc.identifier.urihttp://hdl.handle.net/1885/74904
dc.publisherElsevier
dc.sourceBiochemical Pharmacology
dc.subjectKeywords: alpha synuclein; amyloid; apolipoprotein E2; apolipoprotein E3; apolipoprotein E4; bexarotene; calcineurin; cryopyrin; cytokine; DNA methyltransferase 1; insulin; interleukin 1; interleukin 12; interleukin 17; interleukin 23; membrane receptor; monoclonal Alzheimer's disease; DNA hypomethylation; Insulin resistance; Parkinson's disease, a-Synuclein; TNF
dc.titleTreatment implications of the altered cytokine-insulin axis in neurodegenerative disease
dc.typeJournal article
local.bibliographicCitation.issue7
local.bibliographicCitation.lastpage871
local.bibliographicCitation.startpage862
local.contributor.affiliationClark, Ian A, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationVissel, Bryce, Garvan Institute of Medical Research
local.contributor.authoruidClark, Ian A, a261318
local.description.embargo2037-12-31
local.description.notesImported from ARIES
local.identifier.absfor111500 - PHARMACOLOGY AND PHARMACEUTICAL SCIENCES
local.identifier.ariespublicationf5625xPUB4367
local.identifier.citationvolume86
local.identifier.doi10.1016/j.bcp.2013.07.030
local.identifier.scopusID2-s2.0-84884704633
local.type.statusPublished Version

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Clark_Treatment_implications_of_the_2013.pdf
Size:
881.5 KB
Format:
Adobe Portable Document Format